Market Place
Sourcing Support
Astellas cruises into first DTC campaign for GA med Izervay
30 Sep 2024 //
FIERCE PHARMA
Eric Stonestreet, Partners with Iveric Bio to Raise Awareness of GA
20 Sep 2023 //
PR NEWSWIRE
Iveric Announces Positive 24-Month Topline Results from Phase 3 Study of IZERVAY
18 Sep 2023 //
PR NEWSWIRE
EMA Accepts Iveric`s Marketing Authorization Application for Avacincaptad Pegol
17 Aug 2023 //
PR NEWSWIRE
Iveric Receives FDA Approval for IZERVAY, a New Treatment for Geographic Atrophy
05 Aug 2023 //
PR NEWSWIRE
Astellas Completes Acquisition of Iveric Bio
11 Jul 2023 //
PR NEWSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2023 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2023 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24 May 2023 //
BUSINESSWIRE
Astellas Pharma buys Iveric Bio for $5.9 billion
01 May 2023 //
REUTERS
Iveric Bio New Functional Vision Loss Reduction Data from Avacincaptad Pegol
24 Apr 2023 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Apr 2023 //
BUSINESSWIRE
Iveric Bio: ACP Advances As GATHER Results Continue To Impress
23 Mar 2023 //
PRESS RELEASE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Mar 2023 //
BUSINESSWIRE
Iveric Announces Vision Loss Reduction Data from Avacincaptad Pegol GATHER Trial
01 Mar 2023 //
PRESS RELEASE
Iveric Bio Reports Fourth Quarter and Full Year 2022 Financial Results
01 Mar 2023 //
BUSINESSWIRE
Iveric Bio to Present at the Cowen 43rd Annual Health Care Conference
28 Feb 2023 //
BUSINESSWIRE
Iveric Bio to Report Fourth Quarter and Full Year 2022 Financial Results
22 Feb 2023 //
BUSINESSWIRE
FDA accepts Iveric Bio`s NDA, grants priority review for GA drug
17 Feb 2023 //
ENDPTS
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2023 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Jan 2023 //
BUSINESSWIRE
Opus Genetics acquires two gene therapy candidates from Iveric Bio
29 Dec 2022 //
HEALIO
Iveric Bio Announces Completion of Rolling NDA Sub to FDA for Avacincaptad Pegol
20 Dec 2022 //
BUSINESSWIRE
Intellia and Iveric sell stocks to raise money, each netting $300M
01 Dec 2022 //
ENDPTS
Iveric Bio Announces Proposed Offering of Common Stock
30 Nov 2022 //
BUSINESSWIRE
Iveric Bio Announces Pricing of $300 Million Public Offering of Common Stock
30 Nov 2022 //
BUSINESSWIRE
Iveric Bio receives new therapy designation for avacincaptad pegol
21 Nov 2022 //
PHARMATIMES
Iveric Bio Announces FDA Has Granted Therapy Designation for Avacincaptad Pegol
17 Nov 2022 //
PRESS RELEASE
Iveric- FDA Has Granted Breakthrough Therapy Designation for Avacincaptad Pegol
17 Nov 2022 //
BUSINESSWIRE
Iveric Bio to Present at Upcoming Investor Conferences
04 Nov 2022 //
BUSINESSWIRE
Iveric Bio Reports Third Quarter 2022 Operational Highlights & Financial Results
03 Nov 2022 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Nov 2022 //
BUSINESSWIRE
Iveric Bio to Report Third Quarter 2022 Financial Results
27 Oct 2022 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04 Oct 2022 //
BUSINESSWIRE
Iveric Bio undeterred by looming PDUFA for competitor
30 Sep 2022 //
ENDPTS
CARVYKTI Receives Approval from Japan’s Ministry of Health
27 Sep 2022 //
BUSINESSWIRE
Iveric Bio to Present at Upcoming Investor Conferences
07 Sep 2022 //
BUSINESSWIRE
Iveric Bio reports positive PhIII readout as shares surge, FDA filing planned
07 Sep 2022 //
ENDPTS
Iveric Bio Announces Positive Data from Zimura GATHER2 PIII Trial
06 Sep 2022 //
PRESS RELEASE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Sep 2022 //
BUSINESSWIRE
Iveric Bio To Announce GATHER2 Trial Data In September
26 Aug 2022 //
NASDAQ
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Aug 2022 //
BUSINESSWIRE
Iveric Bio Announces Agreement for Up to $250M in Non-Dilutive Debt Financing
26 Jul 2022 //
BUSINESSWIRE
Iveric Bio Reports Q2 2022 Operational Highlights and Financial Results
26 Jul 2022 //
BUSINESSWIRE
Iveric Bio Announces Post-Hoc Analysis from GATHER1 Trial of Zimura
16 Jul 2022 //
BUSINESSWIRE
Iveric granted rights to commercialise formulations of AMD treatment
15 Jul 2022 //
PMM
Iveric to develop sustained-release form of retinal disease drug
05 Jul 2022 //
FIERCEPHARMA
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Jul 2022 //
BUSINESSWIRE
Iveric Bio Announces Presentation of Post-Hoc Analysis
10 Jun 2022 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Jun 2022 //
BUSINESSWIRE
Iveric Bio to Present at the UBS Global Healthcare Conference 2022
17 May 2022 //
BUSINESSWIRE
Iveric Bio to Participate in the H.C. Wainwright Global Investment Conference
16 May 2022 //
BUSINESSWIRE
Iveric Bio to Report Q1 2022 Financial Results and Host Conference Call
27 Apr 2022 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2022 //
BUSINESSWIRE
Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Mar 2022 //
BUSINESSWIRE
Iveric Bio to Present at the Cowen 42nd Annual Health Care Conference
28 Feb 2022 //
BUSINESSWIRE
Iveric Bio Reports Q4 and Full Year 2021 Operational and Financial Results
24 Feb 2022 //
BUSINESSWIRE
Iveric Bio to Report Q4 and Full Year 2021 Financial Results on Feb 24
17 Feb 2022 //
BUSINESSWIRE
Iveric Bio Shows Foveal Anatomy Post-Hoc Analysis from GATHER1 Trial of Zimura
11 Feb 2022 //
BUSINESSWIRE
Iveric Bio Announces New Post-Hoc Analyses of Zimura from GATHER1 Trial
07 Feb 2022 //
BUSINESSWIRE
